Vertex Pharma Increases Guidance For 2015 KALYDECO Revenues

(RTTNews) - Vertex Pharmaceuticals Incorporated (VRTX) increased its financial guidance for total 2015 KALYDECO revenues and reiterated its guidance for non-GAAP operating expenses. Vertex now expects KALYDECO net revenues of $605 to $620 million for 2015. The prior range, provided on July 29, 2015 by the company, was for KALYDECO net revenues of $575 to $590 million for 2015.

Vertex reiterated its guidance for combined non-GAAP R&D and SG&A expenses in 2015 of $1.05 to $1.10 billion. Total combined non-GAAP R&D and SG&A expenses are expected to be in the middle of the guidance range.

For the third-quarter 2015, KALYDECO product revenues rose 31% to $165.9 million.